Shabnam Khazraei, Seyed Abdolhamid Angaji, Behnaz Beikzadeh, Mitra Salehi, Raheleh Roudi, Behzad Narouie,
Volume 29, Issue 3 (Scientific Journal of Kurdistan University of Medical Sciences 2024)
Abstract
Background and Aim: Prostate Cancer (PC) is one of the most common cancers and the second leading cause of death in Iranian men. Several factors such as age, endogenous hormone balance, genetic factors and environmental factors are involved in PC incidence. The aim of this study was to investigate the association of rs351855 and rs1983891 polymorphisms with prostate cancer risk in Iranian population.
Materials and Methods: In this case-control study 185 peripheral blood samples were taken from 101 patients with prostate cancer and 84 healthy individuals. For SNP genotyping in each sample, Tetra-ARMs PCR method was used.
Results: According to the multi-stage method, 58 individuals were selected in the first stage. p-value<0.4 was considered significant. In relation to rs351855, there was a significant difference between the case and control groups (P<0.16), but, there was no significant difference between the groups in regard to rs1983891 (P<0.62). Therefore, rs1983891 was eliminated at this stage. In the second stage, all samples (184 samples) were analyzed in relation to rs351855 at a significance level of P<0.05. A significant difference was observed between the two groups of case and control in relation to rs351855 polymorphism in all samples (P<0.00). In this study, allelic and genotypic frequencies were investigated in multiplicative and additive genetic models. Our data showed a significant relationship between the multiplicative model allele (A) and the risk of prostate cancer, also the data indicated that the additive model AA vs GG and AG vs GG were associated with PC. On the other hand, this polymorphism was associated with all three levels of PSA and Gleason score.
Conclusion: In the present study rs351855 polymorphism was associated with the risk of prostate cancer in Iran, on the contrary, rs1983891 polymorphism was not associated with prostate cancer risk. rs351855 may be considered as a potential biomarker for the screening of prostate cancer.
